Skip to main content
PMC home page
UKPMC Funders Author Manuscripts logoLink to UKPMC Funders Author Manuscripts
. Author manuscript; available in PMC: 2017 Jun 24.
Published in final edited form as: Bioconjug Chem. 2017 May 10;28(6):1722–1733. doi: 10.1021/acs.bioconjchem.7b00182

Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding

Dominik Summer †, Leo Grossrubatscher †, Milos Petrik ‡, Tereza Michalcikova ‡, Zbynek Novy ‡, Christine Rangger †, Maximilian Klingler †, Hubertus Haas §, Piriya Kaeopookum †,║, Elisabeth von Guggenberg †, Roland Haubner †, Clemens Decristoforo †,*
PMCID: PMC5481817  EMSID: EMS73209  PMID: 28462989

Abstract

Positron emission tomography (PET) as well as optical imaging (OI) with peptide receptor targeting probes have proven their value for oncological applications but also show restrictions depending on the clinical field of interest. Therefore, the combination of both methods, particularly in a single molecule, could improve versatility in clinical routine. This proof of principle study aims to show that a chelator, Fusarinine C (FSC), can be utilized as scaffold for novel dimeric dual-modality imaging agents. Two targeting vectors (a minigastrin analogue (MG11) targeting cholecystokinin-2 receptor overexpression (CCK2R) or integrin αVβ3 targeting cyclic pentapeptides (RGD)) and a near-infrared fluorophore (Sulfo-Cyanine7) were conjugated to FSC. The probes were efficiently labeled with gallium-68 and in vitro experiments including determination of logD, stability, protein binding, cell binding, internalization, and biodistribution studies as well as in vivo micro-PET/CT and optical imaging in U-87MG αVβ3- and A431-CCK2R expressing tumor xenografted mice were carried out. Novel bioconjugates showed high receptor affinity and highly specific targeting properties at both receptors. Ex vivo biodistribution and micro-PET/CT imaging studies revealed specific tumor uptake accompanied by slow blood clearance and retention in nontargeted tissues (spleen, liver, and kidneys) leading to visualization of tumors at early (30 to 120 min p.i.). Excellent contrast in corresponding optical imaging studies was achieved especially at delayed time points (24 to 72 h p.i.). Our findings show the proof of principle of chelator scaffolding for hybrid imaging agents and demonstrate FSC being a suitable bifunctional chelator for this approach. Improvements to fine-tune pharmacokinetics are needed to translate this into a clinical setting.

Introduction

The overexpression of specific receptors in various tumors is utilized in modern nuclear medicine for imaging with radiolabeled peptides. A broad variety of receptors have been identified as promising targets for radiopharmaceutical development and some have been successfully implemented in clinical research and routine practice.1–3 The radionuclide gallium-68 with its availability through modern, cost-effective 68Ge/68Ga-generator systems has become a radiometal of choice for targeted-PET imaging4 and allows detection, staging, or restaging of tumor with high sensitivity. In addition to PET imaging in oncology, intraoperative tracer guidance is a very attractive approach allowing the resection of even the smallest tumor lesions while keeping the risk of surgery related nerve malfunction or unnecessary removal of nondiseased tissue as low as possible. In principle gallium-68 labeled tracers could be used for surgical guidance via direct detection of radioactivity with hand-held gamma probes or by detection of Cerenkov luminescence generated by the emitted positrons (β+). The short half-life of gallium-68 limits this application and the use of alternative radionuclides with longer half-life such as indium-111 increases the radiation burden. Gamma probes also lack the sensitivity to define the tumor margins accurately and Cerenkov luminescence is likely to vanish related to energy levels below the detectable threshold due to absorption and scattering processes. Optical imaging for intraoperative guidance via near-infrared fluorescence is a suitable alternative.5 Under optimal conditions optical imaging can result in a spatial resolution of less than 1 mm generating a unique real-time visualization method to surgeons facilitating complete resection of cancerous cells.6,7 Considering the limited tissue penetration, this method is a more powerful add-on when combined with preoperative PET as a multimodality imaging technique rather than a standalone perioperative imaging method. Several preclinical studies have demonstrated the effectiveness and value of the dual-modality imaging approach.8,9 Due to the availability of novel fluorophores and targeted probes the design of single molecule based dual-modality agents has attracted great interest but also faces challenges regarding choice of fluorophore and conjugation strategy10–12 especially when strategies such as multivalency to enhance the targeting efficiency13 are applied. We have recently shown that Fusarinine C (FSC) has excellent complexing abilities concerning gallium-68 and zirconium-89.14,15 Three primary amines for site-specific conjugation nominate FSC as an adaptable candidate for a dual-modality imaging approach by attaching both a targeting sequence as well as an optical imaging moiety to the chelator used for radiolabeling. Such cyclic chelator based scaffolding for hybrid imaging agents following this new conjugation strategy (Scheme 1) has to our knowledge not been described yet. In this proof of principle study we report on the synthesis and the main characteristics of two different novel divalent FSC-based hybrid imaging agents. A minigastrin analogue (MG11)— targeting cholecystokinin-2 (CCK-2) receptor overexpression being involved in rare diseases like gastrointestinal stromal tumors (GIST) and medullary thyroid carcinoma (MTC)16— and the cyclic pentapeptide (RGD)—targeting integrin αVβ3, a cell adhesion molecule being involved in various cancer malignancies (breast, prostate, pancreatic, ovarian, melanoma, glioblastoma, cervical)17,18—were chosen as model peptides for this preclinical approach.

Scheme 1. Synthesis of Hybrid Imaging Agents (Stereochemistry Omitted).

Scheme 1

Open in a new tab

Results and Discussion

Precursor Preparation

The amino-functionalized chelator (FSC) could be extracted directly from fungal culture via an inhouse C18-cartridge method and iron was added to protect the hydroxamates and prevent any side reactions during further derivatization. Synthesis of thiolated targeting peptides for site specific maleimide conjugation was carried out using straightforward solid-phase peptide synthesis. Double-malei-mide linker modified [Fe]FSC was obtained in moderate yield (>20%, nonoptimized) out of a mixture of mono- and multiple substituted conjugates as three chemically identical primary amines cannot be derivatized individually by NHS-ester reaction strategy. Conjugation of the fluorescent dye to the remaining free amine biding site of the chelator was easily achieved by in situ activation of Sulfo-Cyanine7 carboxylic acid. Targeting vectors were conjugated after demetalation with 50 mM Na2EDTA to obtain the divalent hybrid imaging agents Sulfo-Cy7-FSC-MG and Sulfo-Cy7-FSC-RGD in good yields (>50%). Identity of all compounds was confirmed by MALDI-TOF mass spectrometry. Chemical purity determined by analytical RP-HPLC (UV absorption at λ = 220 nm) was >95% for all intermediates and >93% for the hybrid imaging agents, sufficient for this proof of principle study. From a number of candidates19 the commercially available heptamethine indocyanine based and disulfonated fluorophore—Sulfo-Cyanine—has been considered an appropriate choice as optical signaling moiety. It has an excitation/emission (750/773 nm) in the near-infrared range leading to enhanced tissue penetration and high contrast in imaging, a high quantum yield, high stability, and its high water solubility matches the requirements for in vivo imaging. Additionally, the fact that structurally related indocyanine green (ICG; Cardio-Green) is the only dye being approved as injectable fluorophore for diagnostic applications in patients by the Food and Drug Administration (FDA) so far and has been used successfully in patients for more than 40 years with an excellent toxicity profile strengthened our choice.20 Similar approaches of mono- and divalent hybrid imaging agents targeting integrin αVβ3 have been published21–24 while no comparable approach toward CCK2R targeting has been described so far. Still the architecture of those bioconjugates differs fundamentally from our approach as in the case of LS308 and DTPA-Lys-(IRDye800)-c(KRGDf) the targeting vector as well as fluorescent dye were conjugated via a linker to the same binding site of the bifunctional chelator. In the case of DFO-Cypate-cyclo[RGDfK] the RGD-peptide and the chelator were attached to different binding domains of the fluorophore pointing out that FSC with multiple conjugation sites enables manifold derivatization possibilities compared to commonly used BFCs such as diethylene triamine pentoacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), or deferoxamine (DFO) offering only one functional group for site-specific conjugation.

Radiolabeling with Gallium-68

Both compounds could be labeled according to the detailed protocol in the Experimental Section with the radionuclide obtained from commercial available generator in >99% radiochemical yield (RCY), with >95% radiochemical purity (RCP) and at specific activities (SA) of 113.1 ± 0.94 GBq/μmol (3.06 ± 0.03 Ci/μmol) for Sulfo-Cy7-FSC-MG and 100.9 ± 0.42 GBq/μmol (2.73 ± 0.01 Ci/μmol) for Sulfo-Cy7-FSC-RGD (n = 3; nonoptimized). The radiolabeled tracers were used withouth further purification for all experiments. It is highly noticeable that the formation of the radiometal chelator complex within minutes at room temperature offers mild radiolabeling conditions for sensitive biomolecules. In our case it minimized the risk to oxidize the methionine of Sulfo-Cy7-FSC-MG. This is contrary to ligands conjugated to the macrocyclic bifunctional chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) where heating is mandatory for radiolabeling and is highly advantageous as oxidation leads to a loss of CCK2R affinity.25

In Vitro Characterization

Partition coefficients (logD), protein binding, and stability assessments in fresh human serum and phosphate buffered saline (PBS; pH 7.4) of [68Ga]Sulfo-Cy7-FSC-MG and [68Ga]Sulfo-Cy7-FSC-RGD are summarized in Table 1. LogD values ranging from −1.9 to −2.3 reveal a hydrophilic character for both compounds. Binding to serum proteins was consistent over time and ranged from low for [68Ga]Sulfo-Cy7-FSC-RGD with approximately 20% to high for [68Ga]Sulfo-Cy7-FSC-MG with more than 70%. Compared to a nonfluorescent divalent FSC-MG derivative (logD = −2.5 ± 0.2; protein binding = 16.5 ± 0.1%; unpublished data) lipophilicity and protein binding of [68Ga]Sulfo-Cy7-FSC-MG increased distinctly. As the same trend could be observed comparing [68Ga]Sulfo-Cy7-FSC-RGD to nonfluorescent dimeric probe DOTA-E-[c(RGDfK)]226 or a trivalent FSC-RGD derivative14 this can be attributed to the structural properties of the fluorescent dye. Determination of stability in different media showed no significant release of gallium-68 indicating high complex stability but a slight degradation of the bioconjugates (2–5%) was observed in the serum as well as in the PBS control. Taking into account that fluorophores are sensitive to radiolysis especially in aqueous media,27 RCP after labeling could be improved by radioprotective additives, e.g., ascorbic acid28 and this might also have positive effects regarding stability.

Table 1. Octanol/Water Partition Coefficient (logD), Protein Binding, and Stability in Human Serum (PBS as Control) of 68Ga-Labeled Hybrid Imaging Agents.

[68Ga]Sulfo-Cy7-FSC-MG [68Ga]Sulfo-Cy7-FSC-RGD
Distribution coefficient logD (pH 7.4) −1.9 ± 0.17 −2.3 ± 0.16
Protein binding 1 h 75.9 ± 1.2 20.5 ± 0.7
2 h 74.1 ± 2.1 20.6 ± 0.9
4 h 73.3 ± 1.7 21.6 ± 1.1
Stability in PBS 1 h 95.1 ± 0.2 95.7 ± 0.1
2 h 94.9 ± 0.4 94.7 ± 0.6
4 h 94.4 ± 0.1 94.4 ± 0.3
Stability in serum 1 h 95.5 ± 0.6 94.9 ± 0.8
2 h 94.5 ± 0.5 94.4 ± 0.3
4 h 93.9 ± 0.5 92.6 ± 0.8
Open in a new tab

Cell binding studies are shown in Figure 1 and confirmed a high receptor affinity for both compounds while the difference between metal-free and metal-bound ([natGa]) bioconjugates was negligible. Sulfo-Cy7-FSC-MG showed an IC50 value of 2.81 ± 0.66 and 2.68 ± 0.53 nM in the uncomplexed and complexed form indicating improved binding affinity compared to DOTA-minigastrin11 (9.5 ± 0.5 nM). Despite slight variances in experimental setting resulting IC50 values were comparable with a fluorescence labeled divalent minigastrin derivative (bivQ)29 and nonfluorescent divalent FSC-MG derivative (0.9 ± 0.2 nM; unpublished data). An IC50 value of 1.13 ± 0.22 and 0.81 ± 0.19 nM was determined for metal-free and [natGa] bound Sulfo-Cy7-FSC-RGD showing enhanced affinity compared to c(RGDyV) (15.19 ± 2.86 nM). The affinity for Sulfo-Cy7-FSC-RGD is comparable to a variety of previous published nonfluorescent trivalent FSC-RGD derivatives14,30 but resulted to be higher compared to integrin αVβ3 targeting dimers as Cy7-E[c(RGDyK)]2,31 nonfluorescent DOTA-E-[c(RGDfK)]2,26 HYNIC/DOTA-3PEG4-c(RGDfK)2,32 or the hybrid imaging agent DOTA-(AF)SAv/biotin-PEG-RGD2.24 Therefore, we speculate that our novel synthetic strategy can ensure unaffected peptide/receptor interaction by preventing steric hindrance at the receptor binding site. This theory is strengthened by a recent report on a DOTA based bombesin derivative for hybrid imaging of prostate cancer where receptor affinity decreased significantly compared to nonfluorescent labeled probe when the fluorophore was conjugated to the same binding site as the targeting vector.9

Figure 1.

Figure 1

Open in a new tab

Binding affinity of metal-free and metal-bound Sulfo-Cy7-FSC-MG on A431-CCK2 cells (A) and of Sulfo-Cy7-FSC-RGD on human melanoma M21 (αvβ3-positive) cells (B); IC50 values are expressed as mean of three individual experiments in triplicates ± SD.

Cell uptake studies using radiolabeled conjugates on A431-CCK2R cells for [68Ga]Sulfo-Cy7-FSC-MG and for [68Ga]-Sulfo-Cy7-FSC-RGD on M21 (αvβ3 positive) and M21-L (αvβ3 negative) cells are summarized in Figure 2 indicating highly specific receptor-mediated internalization. The internalized activity for [68Ga]Sulfo-Cy7-FSC-MG resulted in 4.56 ± 0.39% and 8.75 ± 1.32% of total activity after 1 and 2 h incubation. An unspecific membrane bound amount of activity was negligibly low at both time points (0.21 ± 0.08% and 0.31 ± 0.29%). Corresponding blocking studies with CCK2R receptor saturation via addition of pentagastrin in 100-fold molar excess reduced the internalized activity to 0.19 ± 0.1% and 0.44 ± 0.41% while unspecific membrane bound amount remained comparable (0.13 ± 0.06% and 0.25 ± 0.23%). Cell uptake for [68Ga]Sulfo-Cy7-FSC-RGD was 2.45 ± 0.36% and 4.41 ± 1.17% and was reduced to approximately 1/6 by using αvβ3 negative cells (0.43 ± 0.25% and 0.71 ± 0.66%) after 1 and 2 h, respectively. The membrane bound amount of activity was 1.09 ± 0.23% and 1.79 ± 0.59%, respectively, on M21 cells revealing slow internalization while unspecific membrane bound activity was 0.29 ± 0.12% and 0.80 ± 0.62% on M21-L cells.

Figure 2.

Figure 2

Open in a new tab

Radio cell internalization studies after 1 and 2 h incubation of [68Ga]Sulfo-Cy7-FSC-MG using A431-CCK2R cells (A) and of [68Ga]Sulfo-Cy7-FSC-RGD using human melanoma M21 (αvβ3-positive) and M21-L (αvβ3-negative) cells (B).

Fluorescence-determined cell uptake after 2 h incubation (Figure 3) for Sulfo-Cy7-FSC-MG resulted in 10.78 ± 1.04% on nonblocked and 1.65 ± 0.47% on blocked A431-CCK2R cells while Sulfo-Cy7-FSC-RGD showed 5.79 ± 0.88% on αvβ3 positive and 1.74 ± 0.25% on αvβ3 negative cells. Somewhat higher values compared to the radioactive assay may be related to differences in experimental settings, but generally results are very comparable proving receptor specific targeting properties for both compounds in vitro independently whether measured via the radioactive or optical signal.

Figure 3.

Figure 3

Open in a new tab

Fluorescence cell uptake studies after 2 h incubation of Sulfo-Cy7-FSC-MG using A431-CCK2R cells and of Sulfo-Cy7-FSC-RGD using human melanoma M21 (αvβ3-positive) and M21-L (αvβ3-negative) cells.

In Vivo Characterization

The results of the biodistribution studies of [68Ga]Sulfo-Cy7-FSC-MG in A431-CCK2R (receptor positive) and A431-mock (receptor negative; CCK2-) xenografted BALB/c nude mice as well as of [68Ga]Sulfo-Cy7-FSC-RGD in U-87MG (αvβ3 positive) xenograft bearing mice including corresponding tumor-to-organ ratios are presented in Figure 4. [68Ga]Sulfo-Cy7-FSC-MG showed slow pharmacokinetics as the percentage of the injected dose per gram tissue (%ID/g) remained comparable 1 and 2 h after tracer administration. The bioconjugate was highly accumulated in kidneys (71.1 ± 7.0% ID/g 2 h p.i.) and the resulting tumor-to-kidney ratios of <0.5 are in agreement with mono- and divalent CCK2R targeting probes for optical imaging dQ-MG-754,33 QE, and bivQ.29 Slow clearance from the blood indicated by a decrease from 4.7 ± 0.7% to 3.0 ± 0.5% ID/g led to a pronounced accumulation in liver tissue after 2 h (25.7 ± 3.3% ID/g). Furthermore, the prolonged circulation of [68Ga]Sulfo-Cy7-FSC-MG in the blood favored accumulation in non-targeted tissue especially spleen, while tumor uptake with values of 3.1 ± 0.9% and 3.8 ± 0.7% ID/g after 1 and 2 h, respectively, showed no significant difference. Increasing CCK2R to CCK2-ratios of receptor-positive (CCK2R) and -negative (CCK2-) tumors from 1.5 to 3.1 indicated target-specific tumor uptake. [68Ga]Sulfo-Cy7-FSC-RGD was highly accumulated in tumor tissue after 30 min p.i. (10.1 ± 0.8% ID/g) and tumor washout was slow as still 7.5 ± 0.8% ID/g were present in tumor tissue after 90 min. This is in good agreement with reports of nonfluorescent radiolabeled dimeric RGD probes being evaluated on the same integrin αvβ3 expressing tumor model.32,34 [68Ga]Sulfo-Cy7-FSC-RGD was quickly cleared from the blood (decrease of 4.0 ± 0.4% ID/g to 1.3 ± 0.2% ID/g) moderate tracer accumulation in the liver remaining at approximately 6–7% ID/g and high kidney retention ranging from 54.8 ± 1.1% ID/g to 57.3 ± 4.6% ID/g indicates tubular reabsorption. Furthermore, slightly elevated accumulation in nontargeted organs (spleen, stomach, heart, lung) was observed possibly related to physiologic expression of integrins,35 being consistent with reports on [64Cu]-DOTA-(AF)SAv/biotin-PEG-RGD2 24 and [111 In]-LS30823 hybrid imaging agents. The high tumor/bone and tumor/muscle ratios of both bioconjugates (Figure 4C,D) confirmed the high stability found in vitro. However, some 68Ga release cannot be excluded, and in particular the correlation between radionuclide release (influencing the PET signal) and in vivo stability of the FSC-conjugate itself (correlating with the optical signal) warrants further investigation.

Figure 4.

Figure 4

Open in a new tab

Ex vivo biodistribution studies in A431-CCK2R/A431-mock tumor xenografted BALB/c nude mice 1 and 2 h p.i. for [68Ga]Sulfo-Cy7-FSC-MG (A) and for [68Ga]Sulfo-Cy7-FSC-RGD in U-87MG xenograft-bearing mice 30 and 90 min p.i. (B). Corresponding tumor-to-organ ratios are shown for [68Ga]Sulfo-Cy7-FSC-MG (C) and [68Ga]Sulfo-Cy7-FSC-RGD (D) (error bars omitted).

Animal imaging studies including micro-PET/CT as well as optical imaging were conducted in the same tumor mouse model as biodistribution studies and are shown in Figure 5. Static PET images of [68Ga]Sulfo-Cy7-FSC-MG confirmed the results from ex vivo biodistribution showing receptor specific uptake in CCK2R overexpressing tissue and visualized the tumor 60 and 120 min post-injection, but only moderate target-to-organ contrast was observed due to high accumulation of the tracer in liver, spleen, and kidneys not differing very much between the two time points. Optical imaging of Sulfo-Cy7-FSC-MG mainly showed tracer accumulation in nontargeted tissue 1 h p.i., whereas tumor tissue starts to be visualized in moderate contrast 2 h after injection. At later time points from 5 h up to 3 days, respectively, imaging resulted in excellent contrast as the tracer was completely cleared from nontargeted tissue and high accumulation in tumor tissue accompanied by visualized kidneys related to renal retention was observed. Static PET images of [68Ga]Sulfo-Cy7-FSC-RGD showed highly specific receptor uptake as the tumor was visualized clearly accompanied by renal elimination and some minor unspecific binding in the gastrointestinal tract. Fluorescence imaging showed comparable results 30 min p.i. but higher signal for kidney and intestine 90 min and 4 h p.i., respectively, while the best contrast was achieved 24 h after administration. Two days after injection the ligand was completely washed out from tumor tissue being consistent with reports from the literature where different fluorescent-labeled RGD derivatives were investigated.24,31,36 Still there is room for improvement in particular reducing the lipophilic character of the fluorescent dye resulting in slow pharmacokinetics. This was also indicated as in both imaging modalities a non-negligible amount of tracer remained at the injection site showing little reabsorption. For future prospective developments these could be overcome by using fluorophores with a higher degree of sulfonation to increase hydrophilicity and prevent high protein binding ability leading to reduced hepatic clearance and improved imaging contrast. Additionally this concept could also be transferred to other cyclic chelators providing multiple coupling sites, such as TRAP35 or a variety of DOTA/NOTA derivatives37 generating certain scientific value for further developments and clinical application regarding the hybrid imaging approach.

Figure 5.

Figure 5

Open in a new tab

Dual-modality animal imaging studies: Static microPET/CT images (coronal slices) and 3D volume rendered projections of fused microPET/CT (prone position) of [68Ga]Sulfo-Cy7-FSC-MG in A431-CCK2R/A431-mock tumor xenograft-bearing BALB/c nude mice 60 and 120 min p.i. (A) and [68Ga]Sulfo-Cy7-FSC-RGD 30 and 90 min p.i. in mice bearing U-87MG tumor xenografts (C). Corresponding static near-infrared fluorescence images (supine position) at various time intervals are shown in (B) for Sulfo-Cy7-FSC-MG and (D) for Sulfo-Cy7-FSC-RGD.

Conclusion

In this study we successfully used Fusarinine C as the scaffold for novel divalent hybrid imaging bioconjugates by coupling targeting vectors as well as an optical signaling moiety to the chelating core. The resulting dual-modality imaging agents [68Ga]-Sulfo-Cy7-FSC-MG and [68Ga]-Sulfo-Cy7-FSC-RGD showed high radiolabeling yields, excellent stability, and receptor affinity and highly specific receptor targeting properties. Optimization has to be carried out regarding the slow in vivo pharmacokinetics making PET studies using short-lived radionuclides difficult. The described strategy, however, offers a huge variety of possibilities to further improve and optimize in vivo properties toward targeted hybrid imaging in oncology.

Experimental Section

Instrumentation

Analytical [radio]-RP-HPLC

Reversed-phase high-performance liquid chromatography analysis was carried out with a setting as follows: UltiMate 3000 RS UHPLC pump, UltiMate 3000 autosampler, UltiMate 3000 Variable Wavelength Detector (Thermo Fisher Scientific, Vienna, Austria) and a radio detector (GabiStar, Raytest; Straubenhardt, Germany). A Jupiter 4 μm Proteo 90 Å 250 × 4.6 mm (Phenomenex Ltd. Aschaffenburg, Germany) column with a flow rate of 1 mL/min and UV detection at 220 nm was used. Acetonitrile (ACN)/H2O/0.1% trifluoroacetic acid (TFA) was used as mobile phase with following multistep gradient: 0.0–1.0 min 10% ACN, 1.0–12.0 min 10–60% ACN, 12.0–13.0 min 60–80% ACN, 13.0–16.0 min 80% ACN.

Preparative RP-HPLC

RP-HPLC-Purification was performed on a Gilson 322 Pump with a Gilson UV/vis-155 detector and a PrepFC automatic fraction collector (Gilson, Middleton, WI, USA). A Eurosil Bioselect Vertex Plus 30 × 8 mm 5 μm C18A 300 Å precolumn and Eurosil Bioselect Vertex Plus 300 × 8 mm 5 μm C18A 300 Å column (Knauer, Berlin, Germany) were used with a flow rate of 2 mL/min, detection at 220 nm and following ACN/H2O/0.1% TFA multistep gradients: gradient A: 0.0–1.0 min 10% ACN, 1.0–35.0 min 10–60% ACN, 35.0–40.0 min 60% ACN, 40.0–45.0 min 80% ACN; gradient B: 0.0–1.0 min 20% ACN, 1.0–35.0 min 20–60% ACN, 35.0–40.0 min 60% ACN, 40.0–45.0 min. 80% ACN.

MALDI-TOF MS

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was performed on a Bruker microflex benchtop MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) using reflector acquisition mode, positive ion source, and 800 shots per spot. α-Cyano-4-hydroxy-cinnamic acid (HCCA) was chosen as matrix and dried-droplet method for sample preparation on a micro scout target (MSP96 target ground steel BC, Bruker Daltonics). The recorded data was analyzed by Flex Analysis 2.4 software.

Radio-ITLC

Radio instant thin layer chromatography (radio-ITLC) analysis was performed using TLC-SG strips (Varian, Lake Forest, CA, USA) and 0.1 M sodium citrate solution (pH 5). The strips were analyzed using a TLC scanner (Scan-RAM, LabLogistic, Sheffield, UK). Gallium-68 labeled bioconjugates remained at the start (Rf < 0.1) while free radionuclide migrated with the solvent front (Rf > 0.9).

γ-Counter

The radioactivity of all samples was measured in a 2480 Automatic Gamma counter Wizard2 3″ (PerkinElmer, Waltham, MA, USA).

Instrumentation for animal imaging is described below.

Materials and Synthesis

General

All chemicals were purchased from commercial sources as reagent grade and used without further purification unless otherwise stated. Solid-phase peptide synthesis (SPPS) was performed according to standard Fmoc protocols and coupling efficiency was monitored by applying the Kaiser’s Test. The trityl chloride polystyrene resin (TCP, 100–200 mesh) was obtained from PepChem (Reutlingen, Germany). Rink amide MBHA resin (100–200 mesh) and N-terminal 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids were purchased from Novabiochem (La Jolla, CA, USA). Coupling reagents O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium-hexafluorophosphate (HATU) and 1-hydroxy-7-azabenzotriazole (HOAt) were obtained from GenScript Corporation (Piscataway, NJ, USA). All other reagents were from Sigma-Aldrich Handels GmbH (Vienna, Austria) and VWR International GmbH (Vienna, Austria) while Sulfo-Cyanine7 carboxylic acid was purchased from Lumiprobe GmbH (Hannover, Germany). RP-HPLC chromatograms of synthesized compounds are supplied in the Supporting Information.

Peptide Synthesis. [3-MP0-d-Glu1,desGlu2–6]-minigastrin11 [MG11-SH]

The synthesis of the minigastrin analogue ([d-Glu1,desGlu2–6]–Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) was carried out as previously described.38 Briefly, 125 mg of Rink Amide resin (62.5 μmol) was used following Fmoc protocols. For the amino acids Asp and Glu, an OtBu side chain protection was applied, whereas for Trp BOC and for Tyr, tBu protection groups were used and HOAT/HATU activated amino acid coupling was performed for 1 h at ambient temperature using 3-fold molar excess (187.5 μmol). After removing the Fmoc-group from the N-terminal amino acid 3-trithylsulfonylpropionic acid (Bachem, Bubendorf, Switzerland) was coupled to introduce a thiol functionality to the peptide (3-MP0). The peptide was deprotected and cleaved from the resin with TFA/Triisopropylsilane/H2O (v/v/v; 95/2.5/2.5). The crude peptide was precipitated with ice-cold diethyl ether and dissolved in 20% v/v ACN/H2O. The peptide was purified by preparative RP-HPLC (gradient B; tR = 21.6 min) and lyophilized. Analytical data: RP-HPLC tR = 12.02 min; MALDI TOF-MS: m/z [M + Na]+ = 1128.23, [M+K]+ = 1144.24, [C51H64N10O14S2; exact mass: 1105.24 (calculated)].

c(RGDfK)-(PEG)4-SH [RGD-SH]

The cyclic pentapeptide cyclo(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys-) was synthesized by applying Fmoc-based solid-phase peptide synthesis for the linear precursor followed by cyclization according to Haubner and co-workers.39 Modification of the lysine side chain by SAT(PEG)4 coupling and deacetylation was performed following manufacturers protocol. Briefly, the peptide was dissolved in DMF and after adding N-succidimidyl-S-acetyl-(thiotetraethylene glycol) (SAT(PEG)4) in DMSO the reaction mixture was alkalized (pH 9) using DIPEA and stirred for 2 h at RT. The peptide was precipitated with diethyl ether and dried in vacuo. For deacetylation, the crude peptide was dissolved in PBS and 0.5 M hydroxylamine solution was added. The pH was adjusted to 6 and after 2 h reaction time the mixture was purified via preparative RP-HPLC (gradient A; tR = 20.4 min) and dried by lyophilization. Analytical data: RP-HPLC tR = 9.82 min; MALDI TOF-MS: m/z [M + H]+ = 869.52, [C38H61N9O12S; exact mass: 868.01 (calculated)].

Extraction and Derivatization of [Fe]Fusarinine C ([Fe]-FSC)

Fungal culture was carried out under iron deficiency as previously described by Schrettl and co-workers40 with slight changes regarding incubation time and different extraction methods. Briefly, 200 mL of Aspergillus minimal media (AMM) were inoculated with 1 × 106 spores/mL of ΔsidG, an A. fumigatus mutant that lacks conversion of FSC to triacetylfusarine C, and incubated for 28 h at 37 °C and 200 rpm. Hereafter the biomass was filtered off and the filtrate was saturated with iron by adding 100 mM FeCl3 solution. The filtrate (150 mL) was loaded on a Reveleris flash cartridge (C18; 40 μm; 12 g and a column volume (CV) of 18 mL; Grace, Maryland, USA) by using a REGLO tubing pump (Type ISM795, Ismatec SA, Glattbrugg-Zürich, Switzerland) with a flow rate of 15 mL/min. The cartridge fixed [Fe]FSC was washed with one CV of water to remove unbound iron followed by elution with five CV of methanol. After evaporation of the organic solvent and lyophilization approximately 97 ± 10 mg (n = 3) of [Fe]FSC could be obtained as red–brown colored solid with a purity of >90% confirmed by analytical RP-HPLC (tR = 6.8 min.) and the product was used for further synthesis without additional purification. Analytical data: MALDI TOF-MS: m/z [M + H]+ = 780.86, [M + Na]+ = 802.87, [M + K]+ = 818.86, [C33H51FeN6O12; exact mass: 779.63 (calculated)].

[Fe]FSC-(N-(3-maleinimidopropionyl))2 ([Fe]FSC-(mal)2)

7.5 mg [9.6 μmol] [Fe]FSC were dissolved in 1 mL anhydrous dimethylformamide (DMFanh.) and after adding 1 equiv (2.4 mg) of 3-(maleimido)propionic acid (Mal) N-hydroxysuccinimide ester in 500 μL dry DMF and 4 μL N,N-diisopropylethylamine (DIPEA) the mixture was stirred for 2 h at room temperature. The reaction was monitored by analytical RP-HPLC and resulted in a mixture of [Fe]FSC (tR = 6.8 min); [Fe]FSC-mal (tR = 8.1 min); ([Fe]FSC-(mal)2 (tR = 9.5 min); and ([Fe]FSC-(mal)3 (tR = 11.3 min). After evaporation of the organic solvent the residue was dissolved in 20% (v/v) ACN/H2O and purified by preparative RP-HPLC (gradient A; [Fe]FSC-mal (tR = 14.9 min); ([Fe]FSC-(mal)2 (tR = 20.0 min); ([Fe]FSC-(mal)3 (tR = 24.4 min). After lyophilization the amount of the pure product was 2.2 mg. Analytical data: MALDI TOF-MS: m/z [M + H]+ = 1083.34, [M + Na]+ = 1105.41, [C46H58FeN8O18; exact mass: 1081.88 (calculated)].

Conjugation of the Fluorophore. [Sulfo-Cyanine7-FSC-(mal)2]

For the conjugation of the fluorescent dye 1 mg [1.37 μmol] of Sulfo-Cyanine7 carboxylic acid was dissolved in 1 mL DMFanh. and after addition of 1 equiv [0.52 mg] HATU the mixture was left for 10 min at room temperature to activate the carboxylic acid. Subsequently 1.1 equiv of [Fe]FSC-(mal)2 and DIPEA were added and the reaction was stirred for further 30 min. After analytical RP-HPLC confirmed the reaction to be finished the organic solvent was removed under vacuo and 2 mL of 50 mM ethylenediaminetetraacetic acid disodium salt (Na2EDTA) solution were poured onto the crude product and stirring was continued overnight for iron removal (+Fe3+ tR = 11.3 min), -Fe3+ tR = 11.5 min). Finally the product was isolated via preparative RP-HPLC (gradient A: tR = 30.1 min) and freeze-dried. Yield was 1.27 mg [0.73 μmol; 53%] as dark green colored solid. Analytical data: MALDI TOF-MS: m/z [M + H]+ = 1724.37, [M + Na]+ = 1747.54, [C84H107N10O25S2; exact mass: 1720.93 (calculated)].

Conjugation of the Targeting Vectors. Sulfo-Cyanine7-FSC-(mal-peptide)2

For site specific peptide conjugation Sulfo-Cyanine7-FSC-(mal)2 was dissolved in 0.5 mL phosphate buffered saline (PBS) and either RGD-SH or MG11-SH were dissolved in PBS and added in excess. After 30 min at room temperature the reaction solutions were directly purified by preparative RP-HPLC (gradient A, Sulfo-Cy7-FSC-MG tR = 35.6 min and Sulfo-Cy7-FSC-RGD tR = 32.6 min) and the hybrid imaging ligands were lyophilized giving dark green colored solids.

Sulfo-Cyanine7-FSC-(mal-MG11)2 [=Sulfo-Cy7-FSC-MG] 1.30 mg [0.25 μmol; 55%]; analytical data: RP-HPLC tR = 12.6 min; MALDI TOF-MS: m/z [M + H]+ = 3932.09, [M + Na]+ = 3954.98 [C186H235N30O53S6; exact mass: 3931.42 (calculated)].

Sulfo-Cyanine7-FSC-(mal-c(RGDfK)-(PEG4))2 [=Sulfo-Cy7-FSC-RGD] 0.5 mg [0.15 μmol; 58%]; analytical data: RP-HPLC tR = 10.8 min; MALDI TOF-MS: m/z [M + H]+ = 3457.01, [M + Na]+ = 3480.18, [C160H229N28O49S4; exact mass: 3456.95 (calculated)].

Radiochemistry

For radiolabeling 68Ga-chloride was obtained by eluting a commercial 68Ge/68Ga-generator (IGG100, Eckert & Ziegler Isotope products, Berlin, Germany; nominal activity of 1850 MBq) with 0.1 M hydrochloric acid (HCl, Rotem Industries, Israel). Fractionated elution method was used to increase the activity to volume ratio to its maximum. Peptides (10 μg; 2.5–2.9 nmol) were incubated with 100–200 μL eluate (15–35 MBq) and pH was adjusted to 4.5 by adding 20–40 μL 1.14 M sodium acetate solution. After 5 to 10 min incubation at ambient temperature samples were analyzed by radio-RP-HPLC as well as radio-ITLC. Corresponding chromatograms are shown in the Supporting Information.

Distribution Coefficient (logD), Serum Stability, and Protein Binding

[68Ga]Sulfo-Cy7-FSC-MG and [68Ga]Sulfo-Cy7-FSC-RGD (6 MBq) were diluted with phosphate buffered saline to a concentration of 1 μM. Subsequently 50 μL of this solution was added to six Eppendorf tubes containing 450 μL PBS and 500 μL octanol. The mixture was vortexed (1400 rpm) at RT for 15 min using a MS 3 basic vortexer (IKA, Staufen, Germany) followed by centrifugation for 2 min at 4500 rpm. Aliquots of 100 μL of both phases were transferred to plastic vials, measured in the γ-counter and logD values were calculated. For stability testing, radiolabeled tracers were diluted with 450 μL fresh human serum and 450 μL PBS as control to a concentration of 2 μM followed by incubation at 37 °C. After 1, 2, and 4 h (n = 3) 50 μL aliquots were precipitated with acetonitrile (1:1) and centrifuged for 2 min at 14 × 103 rpm. The supernatant was analyzed by radio-RP-HPLC to evaluate for decomposition and corresponding chromatograms are shown in Supporting Information. For protein binding measurement aliquots were analyzed by size exclusion chromatography using MicroSpin G-50 Columns (Sephadex G-50, GE Healthcare, Vienna, Austria) in triplicates. First, the columns were centrifuged at 750 rcf for 1 min to remove the storage buffer. After adding 25 μL of incubation solution columns were centrifuged again for 2 min with 2000 rcf. Column and eluate were measured in the γ-counter and percentages of nonprotein bound radiolabeled peptide (column) and protein bound radiotracer (eluate) were calculated.

Tumor Cell Lines and Cell Culture

Culture media and additives were purchased from Gibco, Invitrogen Corporation, Paisley, UK. All cell lines were grown at 37 °C in a humidified atmosphere of 95% air/5% carbon dioxide and split approximately every 72 h. The human squamous carcinoma cell line A431 transfected with the human CCK-2 receptor (A431-CCK2R)41 and transfected with the empty vector alone (A431-mock) was a kind gift from L. Aloj (Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” - IRCCS, Naples, Italy) and was seeded in tissue culture flasks (Cellstar; Greiner Bio-One, Kremsmuenster, Austria) using Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% v/v fetal bovine serum (FBS) and 1% v/v penicillin-streptomycin-glutamin (PSG) solution. Human melanoma M21 and M21-L (with and without integrin αVβ3 expression) cells were a kind gift from D. A Cheresh (Departments of Immunology and Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA) and were grown in tissue culture flasks using DMEM medium while M21-L cells were maintained in germ count dishes (Greiner Bio-One) in RPMI 1640 cell culture medium both media containing 10% v/v FBS and 1% v/v PSG as additive. Human glioblastoma U-87MG cell line as alternative model for integrin αVβ3 expression was purchased from American Type Culture Collection (ATCC, Manassas, Virginia, USA) and was cultured in tissue culture flasks using Eagle’s Minimum Essential Medium (EMEM) containing 10% v/v FBS as supplement.

In Vitro Studies. CCK-2 Receptor Internalization Assay

To determine the receptor-mediated radioligand uptake A431-CCK2R cells were seeded into 12-well plates (Nunc, Thermo Scientific) with a density of 2 × 106 cells per well and left to grow overnight at 37 °C. At the day of the experiment each well was washed twice with fresh internalization medium (DMEM containing 1% fetal bovine serum) followed by the adjustment to a final volume of 1.2 mL with media. After dividing the plate into an unblocked and blocked compartment (6 wells each) 150 μL PBS/0.5% bovine serum albumin (BSA) solution or 150 μL blocking solution (100-fold molar excess of pentagastrin in PBS/0.5% BSA solution) were added and left for 10 min at room temperature. Hereafter, 150 μL of the radiolabeled peptide (1 nM [68Ga]Sulfo-Cy7-FSC-MG in PBS/0.5% BSA approximately 3 × 104 cpm) was added to each well followed by incubation at 37 °C for 1 and 2 h, respectively. After removal of the supernatant each well was washed two times with 1 mL ice-cold internalization medium and supernatants were collected in plastic vials (wash fraction). For determination of the membrane bound radiotracer cells were incubated twice with 1 mL ice-cold 0.05 M glycine-buffer (pH 2.8) for 5 min collecting the supernatants. Finally, internalized fraction was obtained by lysing the cells with 1 mL of 2 M sodium hydroxide solution (NaOH) two times and collecting the samples. To determine the amount of radiotracer of each fraction all samples were taken for γ-counter measurement against standard solution, i.e., 150 μL radiotracer.

M21/M21-L Internalization Assay

Integrin αvβ3 positive (M21) and αvβ3 negative (M21-L) cells were diluted with incubation medium, i.e., corresponding growth medium containing 1% glutamine (m/v), 1% BSA (m/v), CaCl2 (1 mM), MgCl2 (1 mM), and MnCl2 (10 mM) to a concentration of 2.0 × 106 cells/ml. Aliquots of one milliliter were transferred to Eppendorf tubes and six technical replicates for each cell line were incubated for 1 h at 37 °C. Subsequently 50 μL of the radiolabeled ligand (1.2 nM [68Ga]Sulfo-Cy7-FSC-RGD in PBS/0.5% BSA, approximately 2 × 104 cpm) were added and incubated at 37 °C for further 60 and 120 min, respectively. After incubation the tubes were centrifuged (2 min, 5000 rpm; Eppendorf Centrifuge 5424, Hamburg, Germany) and the supernatant was removed and collected. Hereafter the cells were washed twice with 1 mL ice-cold washing buffer (10 mM TRIS-buffered saline, pH 7.3) and the fractions were combined with the supernatant (wash fraction). To determine the membrane bound tracer amount cells were washed two times with 1 mL acetate buffer (20 mM, pH 4.5, 10 min at 37 °C) and the supernatant was collected. The residual cells were lysed by adding 1 mL of 2 M NaOH twice and collected in plastic vials (internalized fraction). The activity of all collected vials was measured in the γ-counter and compared to standard solution (50 μL radiotracer).

Fluorescence Measured Cell Specificity

Fluorescence assays were conducted similarly to the internalization assays except for using lower cell numbers and determining only the cellbound fraction. Briefly, A431-CCK2R, M21, and M21-L cells were diluted in corresponding media to a density of 2 × 106 cells/mL. Aliquots of 0.5 mL were transferred to Eppendorf tubes—six technical replicates for A431-CCK2R unblocked and blocked and M21/M21-L, respectively—and treated in the same manner as described above. The nonradiolabeled particular ligand was added to a final concentration of 3 nM and the tubes were kept in an incubator (Incubator hood TH15 and Compact shaker KS-15 control, Edmund Bühler GmbH, Hechingen, Germany) at 37 °C for 2 h under vigorously shaking (420/min). After centrifugation (2 min, 5000 rpm) washing steps were performed as mentioned before. Finally, each residual cell pellet was suspended in 200 μL of phosphate buffered saline (pH 7.35) and transferred carefully to a 96-well flat bottom white polystyrol plate (ThermoFischer Scientific-Nunclon). Fluorescence intensity was measured with Tecan Infinite 200 PRO series multiplate reader (Tecan Trading AG, Switzerland) by using Tecan Icontrol 1.1 software. Parameters were set as follows: Fluorescence Top reading; excitation/emission wavelength 740/790 nm; excitation bandwidth 9 nm; emission bandwidth 20 nm; gain optimal; number of flashes 25; integration time 25 μs. Results were calculated and expressed as percentage of cell-bound fluorescence in relation to the standards sample.

Whole Cell Receptor Binding Affinity (IC50) Studies. General

Receptor binding affinities were evaluated via a displacement cell-binding assay for metal free as well as metal bound ([natGa]) conjugates. Binding of nonradioactive gallium was performed in analogy to the radiolabeling procedure but instead of the generator eluate a 100-fold molar excess of gallium bromide (GaBr3) dissolved in 100 μL 0.1 N HCl was used. Cells were prepared as described below and incubated with increasing concentrations [0.001–1000 nM] of competitor in triplicate. After addition of corresponding iodinated radioligand the 96-well MulitScreen Filter Plates HTS (1 μm glass fiber filter, Merck Millipore, Darmstadt, Germany) were incubated for 1 or 2 h at RT under shaking conditions (Compact shaker KS-15 control, 200/min) and after a washing step the remaining activity on the filter was measured in the γ-counter. The receptor affinity of DOTA-minigastrin11 as well as c(RGDyV) were determined under the corresponding conditions as a reference. IC50 values were calculated by using nonlinear curve fitting with following formula NS+SB/(1+x/IC50) on Origin 6.1 software (Northampton, MA, USA). A detailed description regarding iodination can be found in the Supporting Information.

A431-CCK2R cells were diluted in 50 mM HEPES buffer (pH 7.3) containing 5 mM MgCl2 and 0.3% BSA to a density of 5 × 106 cells/mL. 96-well plates were washed with 200 μL of 10 mM TRIS buffered saline (pH 7.3) and 100 μL of cell suspension were added to each well. Hereafter 50 μL of competitor solution {([natGa])Sulfo-Cy7-FSC-MG or DOTA-minigastrin11 diluted in 20 mM HEPES; 10 mM MgCl2 and 0.1% BSA} of each concentration were added and left for 10 min at RT. After incubation with 50 μL of radioligand (human [125I]-[Leu15]-Gastrin I 4.5 × 104 cpm) for 1 h the plate was washed twice with 200 μL TRIS-buffer/well.

Integrin binding affinity assay was adapted from Yun Wu et al.31 Briefly, M21 cells were washed two times with phosphate buffered saline followed by suspension in binding buffer (=20 mM TRIS pH 7.4 + 150 mM NaCl + 2 mM CaCl2 + 1 mM MgCl2 + 1 mM MnCl2 0.1% BSA). 96-well plates were washed with 200 μL of 20 mM TRIS-buffer and seeded with 1 × 106 cells/well (107 cells/mL). After 10 min of incubation in the presence of the competitor {([natGa])Sulfo-Cy7-FSC-RGD or c(RGDyV) diluted in binding buffer)} volume was adjusted to 200 μL/well by adding 50 μL of radioligand ([125I]-c(RGDyV), 4.5 × 104 cpm) and the plate was left for 2 h at RT. Finally the supernatant was removed by vacuum and each well was washed three times with 200 μL ice-cold binding buffer.

Animal Experiments. General

All animal experiments were conducted in accordance with regulations and guidelines of the Czech Animal Protection Act (No. 246/1992), and with the approval of the Czech Ministry of Education, Youth, and Sports (MSMT-22421/2013–12), and the institutional Animal Welfare Committee of the Faculty of Medicine and Dentistry of Palacky University in Olomouc. The studies were performed using female 8–10-week-old athymic BALB/c nude mice (Envigo, Horst, The Netherlands). The number of animals was reduced as much as possible (n = 3 per group and time point for all experiments) and retro-orbital (r.o.) tracer injection as well as small animal imaging was carried out under 2% isoflurane anesthesia (FORANE, Abbott Laboratories, Abbott Park, IL, USA) to minimize animal suffering.

Tumor Xenograft Preparation, Ex Vivo Biodistribution, and Small Animal Imaging Studies

Tumor xenografts were established near the front shoulder of mice by subcutaneous injection of 5 × 106 cells (U-87 MG) or 2 × 106 cells (A431-CCK2R) and the same amount of A431-mock cells as a control in 200 μL appropriate medium and Matrigel (1:1). The tumors were allowed to grow until they had reached a volume of 0.2 to 0.5 cm3. To evaluate ex vivo biodistribution mice were injected with 1–2 MBq (0.05–0.14 nmol) of radiotracer per mouse and mice were sacrificed by cervical dislocation after 30 and 90 min for [68Ga]Sulfo-Cy7-FSC-RGD and after 1 and 2 h in the case of [68Ga]Sulfo-Cy7-FSC-MG. Tumors, blood, muscle tissue, and organs were extracted, weighed, and activity uptake of the samples was measured in the gamma counter. Results were expressed as percentage of injected dose per gram tissue (% ID/g). In vivo PET and CT images were acquired with an Albira PET/SPECT/CT small animal imaging system (Bruker Biospin Corporation, Wood-bridge, CT, USA). Xenograft bearing mice were injected with radiolabeled peptides in a dose of ~5 MBq corresponding to 1–2 μg (0.25–0.58 nmol) of peptide per mouse. Anaesthetized animals were positioned prone head first in the Albira system before the start of imaging. Static PET/CT imaging was carried out 30 and 90 min p.i. for [68Ga]Sulfo-Cy7-FSC-RGD. Animals injected with [68Ga]Sulfo-Cy7-FSC-MG were imaged 1 and 2 h p.i. A 10 min PET scan (axial FOV 148 mm) was performed, followed by a CT scan (axial FOV 65 mm, 45 kVp, 400 μA, at 400 projections). Scans were reconstructed with the Albira software (Bruker Biospin Corporation, Woodbridge, CT, USA) using the maximum likelihood expectation maximization (MLEM) and filtered backprojection (FBP) algorithms. After reconstruction, acquired data was viewed and analyzed with PMOD software (PMOD Technologies Ltd., Zurich, Switzerland). 3D images were obtained using VolView software (Kitware, Clifton Park, NY, USA). Near-infrared in vivo fluorescence imaging was performed with an In-Vivo MS FX PRO small animal imaging system (Bruker Biospin Corporation, Woodbridge, CT, USA). Sulfo-Cy7-FSC-MG and Sulfo-Cy7-FSC-RGD were injected in a dose of 0.25–0.58 nmol per mouse and after supine head first positioning, imaging was conducted in various time intervals up to 72 h p.i. An appropriate filter set (excitation = 730 nm and emission = 790 nm) was used for acquiring the Sulfo-Cy7-FSC-peptide - fluorescence in vivo. Identical illumination settings (acquisition time = 15 s, filters = 730/790 nm, f-stop = 2.8, field of view = 100 mm, and binning = 4 × 4) were used for acquiring all images, and fluorescence emission was normalized to photons/s/mm2. Images were acquired and analyzed using Bruker MI SE software (Bruker Biospin Corporation, Woodbridge, CT, USA).

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.bioconjchem.7b00182.

Experimental details on iodination of ligands used for displacement assay, detailed RP-HPLC chromatograms of all synthetical intermediates and final bioconjugates, analysis of 68Ga-labeled hybrid imaging agents (ITLC/HPLC) and corresponding stability studies in human serum and PBS (HPLC) (PDF)

Supporting Information

Acknowledgments

The authors gratefully acknowledge the financial support of the Austrian Science Foundation (FWF) grants P 25899-B23 and I 1346, financial support from Ministry of Education, Youth and Sports of the Czech Republic (LO1304) and Technology Agency of the Czech Republic (TE01020028). Furthermore, we highly appreciate Heinz Zoller and Nadja Baumgartner, Department of Internal Medicine II, Innsbruck Medical University, for making MALDI-TOF analysis available. We address special thanks to Andreas Ritsch and Tamara Bernscherer, Department of Internal Medicine I, Innsbruck Medical University for their excellent technical assistance regarding fluorescence measurements on Tecan Infinite 200 PRO series.

Abbreviations

PET

positron emission tomography

CT

computed tomography

OI

optical imaging

FSC

fusarinine C

MG

minigastrin

CCK2R

cholecystokinin-2 receptor

RGD

integrin αVβ3 targeting cyclic pentapeptide

p.i.

post-injection

NHS

N-hydroxysuccinimide

RCY

radiochemical yield

RCP

radiochemical purity

SA

specific activity

MALDI-TOF MS

matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

RP-HPLC

reversed-phase high-performance liquid chromatography

ITLC

instant thin layer chromatography

DOTA

1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid

DTPA

diethylene triamine pentoacetic acid

DFO

deferoxamine

PBS

phosphate buffered saline

TRIS

tris-(hydroxymethyl)aminomethane

EDTA

ethylenediaminetetra-acetic acid

% ID/g

percentage injected dose per gram

ACN

acetonitrile

TFA

trifluoroacetic acid

DMF

dimethylformamide

DIPEA

N,N-diisopropylamine

RT

room temperature

Fmoc

9-fluorenylmethyl chloroformate

Footnotes

iD

ORCID

Leo Grossrubatscher: 0000-0002-7705-4168

Clemens Decristoforo: 0000-0003-0566-4036

Notes

The authors declare no competing financial interest.

References

  • (1).Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor Receptor Imaging. J Nucl Med. 2008;49:149S–163S. doi: 10.2967/jnumed.107.045963. [DOI] [PubMed] [Google Scholar]
  • (2).Laverman P, Sosabowski JK, Boerman OC, Oyen WJ. Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging. 2012;39:S78–S92. doi: 10.1007/s00259-011-2014-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (3).Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide Imaging and Therapy in Europe. J Nucl Med. 2011;52:42S–55S. doi: 10.2967/jnumed.110.085753. [DOI] [PubMed] [Google Scholar]
  • (4).Velikyan I. Prospective of 68Ga-Radiopharmaceutical development. Theranostics. 2014;4:47–80. doi: 10.7150/thno.7447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (5).van Leeuwen FWB, de Jong M, Evangelista L, Barbet J, del Vecchio S, Schibli R. Molecular imaging: the emerging role of optical imaging in nuclear medicine. Eur J Nucl Med Mol Imaging. 2014;41:2150–2153. doi: 10.1007/s00259-014-2845-0. [DOI] [PubMed] [Google Scholar]
  • (6).Owens EA, Henary M, El Fakhri G, Choi HS. Tissue-Specific Near-Infrared Fluorescence Imaging. Acc Chem Res. 2016;49:1731–1740. doi: 10.1021/acs.accounts.6b00239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (7).Zhu B, Godavarty A. Near-Infrared Fluorescence-Enhanced Optical Tomography. BioMed Res Int. 2016;10:1. doi: 10.1155/2016/5040814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (8).Lütje S, Rijpkema M, Helfrich W, Oyen WJG, Boerman OC. Targeted Radionuclide and Fluorescence Dual-modality Imaging of Cancer: Preclinical Advances and Clinical Translation. Mol Imaging Biol. 2014;16:747–755. doi: 10.1007/s11307-014-0747-y. [DOI] [PubMed] [Google Scholar]
  • (9).Zhang H, Desai P, Koike Y, Houghton J, Carlin SD, Tandon N, Touijer K, Weber WA. Dual modality imaging of prostate cancer with a fluorescent and radiogallium-labeled GRP receptor antagonist. J Nucl Med. 2017;58:29–35. doi: 10.2967/jnumed.116.176099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (10).Louie A. Multimodality imaging probes: Design and challenges. Chem Rev. 2010;110:3146–3195. doi: 10.1021/cr9003538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (11).Ha Y, Choi HK. Recent conjugation strategies of small organic fluorophores and ligands for cancer-specific bioimaging. Chem-Biol Interact. 2016;248:36–51. doi: 10.1016/j.cbi.2016.02.006. [DOI] [PubMed] [Google Scholar]
  • (12).Sun Y, Ma X, Cheng K, Wu B, Duan J, Chen H, Bu L, Zhang R, Hu X, Deng Z, Xing L, Hong X. Strained cyclooctyne as a molecular platform for construction of multimodal imaging probes. Angew Chem Int Ed. 2015;54:5981–5984. doi: 10.1002/anie.201500941. [DOI] [PubMed] [Google Scholar]
  • (13).Carlucci G, Ananias HJK, Yu Z, Van de Wiele C, Dierckx RA, de Jong IJ, Elsinga PH. Multimerization improves targeting of peptide radio-pharmaceuticals. Curr Pharm Des. 2012;18:2501–2516. doi: 10.2174/13816128112092501. [DOI] [PubMed] [Google Scholar]
  • (14).Knetsch PA, Zhai C, Rangger C, Blatzer M, Haas H, Kaeopookum P, Haubner R, Decristoforo C. [68Ga]-FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation. Nucl Med Biol. 2015;42:115–122. doi: 10.1016/j.nucmedbio.2014.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (15).Zhai C, Summer D, Rangger C, Franssen GM, Laverman P, Haas H, Petrik M, Haubner R, Decristoforo C. Novel Bifunctional Cyclic Chelator for 89Zr Labeling-Radiolabeling and Targeting Properties of RGD Conjugates. Mol Pharmaceutics. 2015;12:2142–50. doi: 10.1021/acs.molpharmaceut.5b00128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (16).Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev. 2006;86:805–847. doi: 10.1152/physrev.00014.2005. [DOI] [PubMed] [Google Scholar]
  • (17).Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stöcklin G, Schwaiger M. Radiolabeled αvβ3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061–1071. [PubMed] [Google Scholar]
  • (18).Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists. J Am Chem Soc. 1996;118:7461–7472. [Google Scholar]
  • (19).Gibbs SL. Near infrared fluorescence for image-guided surgery. Quant Imaging Med Surg. 2012;2:177–87. doi: 10.3978/j.issn.2223-4292.2012.09.04. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (20).Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol. 2003;7:626–634. doi: 10.1016/j.cbpa.2003.08.007. [DOI] [PubMed] [Google Scholar]
  • (21).Li C, Wang W, Wu Q, Ke S, Houston J, Sevick-Muraca E, Dong L, Chow D, Charnsangavej C, Gelovani JG. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol. 2006;33:349–358. doi: 10.1016/j.nucmedbio.2006.01.001. [DOI] [PubMed] [Google Scholar]
  • (22).Ye Y, Bloch S, Xu B, Achilefu S. A Novel Near-Infrared Fluorescent Integrin Targeted DFO Analog. Bioconjugate Chem. 2008;19:225–234. doi: 10.1021/bc7003022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (23).Edwards WB, Akers WJ, Ye Y, Cheney PP, Bloch S, Laforesta R, Achilefu S. Multimodal Imaging of Integrin Receptor-Positive Tumors by Bioluminescence, Fluorescence, Gamma Scintigraphy and SPECT Methods Using a Cyclic RGD Peptide Labeled with a Near Infrared Fluorescent Dye and a Radionuclide. Mol Imaging. 2009;8:101–110. [PMC free article] [PubMed] [Google Scholar]
  • (24).Kang CM, Koo H-J, An GI, Choe YS, Choi JY, Lee K-H, Kim B-T. Hybrid PET/optical imaging of integrin αVβ3 receptor expression using a 64Cu-labeled streptavidin/biotin-based dimeric RGD peptide. EJNMMI Res. 2015 doi: 10.1186/s13550-015-0140-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (25).Breeman WAP, Fröberg AC, de Blois E, van Gameren A, Melis M, de Jong M, Maina T, Nock BA, Erion JL, Mäcke HR. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl Med Biol. 2008;35:839–849. doi: 10.1016/j.nucmedbio.2008.09.006. [DOI] [PubMed] [Google Scholar]
  • (26).Dijkgraaf I, Yim C-B, Franssen GM, Schuit RC, Luurtsema G, Liu S, Oyen WJG, Boerman OC. PET imaging of αvβ3 integrin expression in tumours with 68Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging. 2011;38:128–137. doi: 10.1007/s00259-010-1615-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (27).Rauf MA, Ashraf SS. Radiation induced degradation of dyes-An overview. J Hazard Mater. 2009;166:6–16. doi: 10.1016/j.jhazmat.2008.11.043. [DOI] [PubMed] [Google Scholar]
  • (28).Hernandez R, Heskamp S, Rijpkema M, Bos DL, Goldenberg DM, McBride WJ, Morgenstern A, Bruchertseifer F, Cai W, Boerman OC. Preventing Radiobleaching of Cyanine Fluorophores Enhances Stability of Nuclear/NIRF Multi-modality Imaging Agents. Theranostics. 2017;7:1–8. doi: 10.7150/thno.15124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (29).Kossatz S, Mansi R, Béhé M, Czerney P, Hilger I. Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties. EJNMMI Res. 2013;3:75. doi: 10.1186/2191-219X-3-75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (30).Zhai C, Franssen GM, Petrik M, Laverman P, Summer D, Rangger C, Haubner R, Haas H, Decristoforo C. Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [68Ga]NODAGA-RGD—In Vivo Imaging Studies in Human Xenograft Tumors. Mol Imaging Biol. 2016;18:758–767. doi: 10.1007/s11307-016-0931-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (31).Wu Y, Cai W, Chen X. Near-infrared fluorescence imaging of tumor integrin αvβ3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol. 2006;8:226–236. doi: 10.1007/s11307-006-0041-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (32).Shi J, Kim Y-S, Zhai S, Liu Z, Chen X, Liu S. Bioconjugate Chem. 2009;20:750–759. doi: 10.1021/bc800455p. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (33).Kossatz S, Béhé M, Mansi R, Saur D, Czerney P, Kaiser WA, Hilger I. Multifactorial diagnostic NIR imaging of CCK2R expressing tumors. Biomaterials. 2013;34:5172–5180. doi: 10.1016/j.biomaterials.2013.03.073. [DOI] [PubMed] [Google Scholar]
  • (34).Shi J, Kim Y-S, Chakraborty S, Jia B, Wang F. 2-Mercaptoacetylglycylglycyl (MAG2) as a Bifunctional Chelator for 99mTc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics. Bioconjugate Chem. 2009;20:1559–1568. doi: 10.1021/bc9001739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (35).Notni J, Pohle K, Wester HJ. Be spoilt for choice with radiolabelled RGD peptides: Preclinical evaluation of 68Ga-TRAP(RGD)3. Nucl Med Biol. 2013;40:33–41. doi: 10.1016/j.nucmedbio.2012.08.006. [DOI] [PubMed] [Google Scholar]
  • (36).Liu L, Lin G, Yin F, Law W-C, Yong K-T. Near-infrared fluorescent peptide probes for imaging of tumor in vivo and their biotoxicity evaluation. J Biomed Mater Res, Part A. 2016;104A:910–916. doi: 10.1002/jbm.a.35628. [DOI] [PubMed] [Google Scholar]
  • (37).Brechbiel MW. Bifunctional chelates for metal nuclides. Q J Nucl Med Mol Imaging. 2008;52:166–173. [PMC free article] [PubMed] [Google Scholar]
  • (38).Pfister J, Summer D, Rangger C, Petrik M, von Guggenberg E, Minazzi P, Giovenzana GB, Aloj L, Decristoforo C. Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue. EJNMMI Res. 2015 doi: 10.1186/s13550-015-0154-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (39).Haubner R, Kuhnast B, Mang C, Weber Wa, Kessler H, Wester H-J, Schwaiger M. [18F]Galacto-RGD: Synthesis, Radiolabeling, Metabolic Stability, and Radiation Dose Estimates. Bioconjugate Chem. 2004;15:61–69. doi: 10.1021/bc034170n. [DOI] [PubMed] [Google Scholar]
  • (40).Schrettl M, Bignell E, Kragl C, Sabiha Y, Loss O, Eisendle M, Wallner A, Arst HN, Haynes K, Haas H. Distinct roles for intra- and extracellular siderophores during Aspergillus fumigatus infection. PLoS Pathog. 2007;3:e128. doi: 10.1371/journal.ppat.0030128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (41).Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, De Luca S, Arra C, Pedone C, Morelli G, Salvatore M. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-b receptor imaging. J Nucl Med. 2004;45:485–494. [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information
NIHMS73209-supplement-Supporting_Information.pdf (1.8MB, pdf)

RESOURCES